Brookline Capital Management issued their Q3 2025 earnings estimates for shares of CRISPR Therapeutics in a report released ...

The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by Barclays from $55.00 to $56.00 in a note ...

A CRISPR-based system that erases itself from fly populations may offer a safer approach to tackling insecticide resistance ...

Autophagy is the process by which cells digest and renew their internal structures, recycling damaged or malfunctioning ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

Neuropsychiatric disorders are becoming increasingly prevalent. Given their complex and multifactorial pathogenesis, there is ...

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...